Blood platelets can provide a reservoir for nucleic acids derived from infected cells, including viral, bacterial, and fungal RNA and/or DNA nucleic acids. We are actively seeking partners for the co-development of platelet-powered diagnostics of infectious diseases.


Sales of molecular diagnostic tests for infectious diseases generate approximately 60% of overall molecular diagnostics market revenues, and primarily include tests for human immunodeficiency virus (HIV), HPV, hepatitis B and C (HBV/HCV), and chlamydia and gonorrhea (CT/NG). Beyond HIV, HPV, HBV/HCV, and CT/NG, companies are quickly introducing molecular diagnostic tests for many other infectious disease indications:
Including West Nile Virus, Clostridium difficile (C-diff), methicillin-resistant Staphylococcus aureus (MRSA), respiratory syncytial virus, influenza, pneumonia, Trichomonas vaginalis, genital mycoplasma, herpes simplex virus, norovirus, rotavirus, tuberculosis, and meningitis. Among these, the two tests for diagnosing nosocomial infections, or healthcare-acquired infections (HAIs) – C. Diff and MRSA – have witnessed the greatest level of adoption.